Last updated on January 2019

Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma


Brief description of study

The purpose of this study is to investigate efficacy and safety of R-GemOx Versus R-miniCHOP as first-line treatment of elderly patients with Diffuse large B cell lymphoma

Detailed Study Description

Gemcitabine and Oxaliplatin(GemOx) shows effective activity in patients with relapsed diffuse large-cell lymphoma and other solid tumors. Our Previous study showed that two-weekly regimen of rituximab combined with GemOx regimen acheived comparable response rate to R-miniCHOP.The investigators therefore design this open-label,phase III and random trial to compared the safety and efficacy of R-Gemox versus R-miniCHOP as first-line treatment of elderly patients with diffuse large B cell lymphoma.

Primary Outcome Measures:

2-year overall survival rate

Secondary Outcome Measures:

  • 2-year progression free survival rate
  • overall response rate
  • safety and toxicity Enrollment:258 Study Start Date: June 2016 Primary Completion Date: June 2019

Clinical Study Identifier: NCT02767674

Contact Investigators or Research Sites near you

Start Over

Jianfeng Zou

Tongji Medical College of HUST
Wuhan, China
  Connect »

Wei Xu, M.D., Ph.D.

The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)
NanJing, China
  Connect »

Luqun Wang, M.D., Ph.D.

QiLu Hospital of Shandong University
Jinan, China
  Connect »

Xin Wang, M.D., Ph.D.

Shandong Province Hospital
Jinan, China
  Connect »

Weili Zhao, M.D., Ph.D.

Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China
  Connect »

Ye Guo, M.D., Ph.D.

Sudan University Shanghai Cancer Center
Shanghai, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.